2021
26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial
Duffin K, Gold L, Leonardi C, Pariser D, Green L, Sofen H, Strober B, Chen M, Wang A, Papp K. 26085 Key efficacy and safety of apremilast in patients with mild to moderate plaque psoriasis in the phase 3 ADVANCE trial. Journal Of The American Academy Of Dermatology 2021, 85: ab83. DOI: 10.1016/j.jaad.2021.06.356.Peer-Reviewed Original ResearchEfficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study
Van Voorhees A, Gold L, Lebwohl M, Strober B, Sofen H, Papp K, Bagel J, Zhang Z, Paris M, Wang Y. Efficacy and safety of apremilast in patients with moderate‐to‐severe plaque psoriasis of the scalp: results up to 32 weeks from a randomized, phase III study. British Journal Of Dermatology 2021, 185: 840-842. PMID: 33763874, PMCID: PMC8518877, DOI: 10.1111/bjd.20083.Peer-Reviewed Original Research
2020
Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study
Van Voorhees A, Stein Gold L, Lebwohl M, Strober B, Lynde C, Tyring S, Cauthen A, Sofen H, Zhang Z, Paris M, Wang Y. Efficacy and safety of apremilast in patients with moderate to severe plaque psoriasis of the scalp: Results of a phase 3b, multicenter, randomized, placebo-controlled, double-blind study. Journal Of The American Academy Of Dermatology 2020, 83: 96-103. PMID: 32032692, DOI: 10.1016/j.jaad.2020.01.072.Peer-Reviewed Original ResearchConceptsSevere scalp psoriasisNumeric rating scaleItch Numeric Rating ScaleDermatology Life Quality IndexSafety of apremilastScalp psoriasisPhase 3bWeek 16Inadequate response/intolerancePhysician Global Assessment responseCommon adverse eventsPhysician global assessmentPlacebo-controlled studySevere plaque psoriasisDouble-blind studyProportion of patientsLife Quality IndexPruritic areaPlaque psoriasisPrimary endpointSecondary endpointsAdverse eventsMore patientsMild diseasePsoriasis therapy
2017
Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study)
Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson J, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients with Moderate Plaque Psoriasis with Lower BSA (UNVEIL Phase IV Study). SKIN The Journal Of Cutaneous Medicine 2017, 1: s11. DOI: 10.25251/skin.1.supp.10.Peer-Reviewed Original ResearchEfficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study.
Strober B, Bagel J, Lebwohl M, Stein Gold L, Jackson J, Chen R, Goncalves J, Levi E, Callis Duffin K. Efficacy and Safety of Apremilast in Patients With Moderate Plaque Psoriasis With Lower BSA: Week 16 Results from the UNVEIL Study. Journal Of Drugs In Dermatology 2017, 16: 801-808. PMID: 28809995.Peer-Reviewed Original ResearchConceptsModerate plaque psoriasisSafety of apremilastPlaque psoriasisGlobal assessment scoreStatic Physician's Global Assessment scoreDermatology Life Quality Index scoresUpper respiratory tract infectionPhysician Global Assessment scoreLife Quality Index scoresPercentage changePrior topical therapyMost adverse eventsPrimary efficacy endpointSevere plaque psoriasisTreatment Satisfaction QuestionnaireRespiratory tract infectionsHigh patient satisfactionMean percentage changeQuality Index scoresQuality of lifeGreater percentage changeEfficacy endpointAdverse eventsTopical therapyTract infections